The Prognostic Value of Erythrocyte Polyamine in the Post-Nephrectomy Stratification of Renal Cell Carcinoma Specific Mortality
| Autor: | Giovanni Lughezzani, Françoise Bouet, Nathalie Rioux-Leclercq, Jean Jacques Patard, B. Cipolla, Pierre I. Karakiewicz, Jean Philippe Moulinoux, Véronique Catros-Quemener, Paul Perrotte, Pierre Bigot |
|---|---|
| Přispěvatelé: | Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'urologie, Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Department of urology, Università Vita-Salute San Raffaele, Cancer Prognostics and Health Outcomes Unit, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Privé Saint-Grégoire, Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), De Villemeur, Hervé |
| Rok vydání: | 2010 |
| Předmět: |
Male
Oncology Pathology [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery Spermidine medicine.medical_treatment Spermine Nephrectomy [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology chemistry.chemical_compound MESH: Aged 80 and over 0302 clinical medicine Renal cell carcinoma Prospective Studies MESH: Spermine MESH: Spermidine Aged 80 and over MESH: Aged 0303 health sciences MESH: Middle Aged MESH: Carcinoma Renal Cell Middle Aged Prognosis Kidney Neoplasms 3. Good health Survival Rate MESH: Young Adult 030220 oncology & carcinogenesis Female Adult medicine.medical_specialty MESH: Survival Rate Urology [SDV.CAN]Life Sciences [q-bio]/Cancer [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery MESH: Prognosis Young Adult 03 medical and health sciences [SDV.CAN] Life Sciences [q-bio]/Cancer Internal medicine medicine Carcinoma Humans Carcinoma Renal Cell Aged Retrospective Studies 030304 developmental biology MESH: Humans business.industry Cancer MESH: Adult MESH: Retrospective Studies medicine.disease [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology MESH: Prospective Studies MESH: Male MESH: Nephrectomy chemistry MESH: Kidney Neoplasms Polyamine business MESH: Female Kidney cancer |
| Zdroj: | Journal of Urology Journal of Urology, Elsevier, 2010, 183 (2), pp.486-91. ⟨10.1016/j.juro.2009.10.012⟩ Journal of Urology, 2010, 183 (2), pp.486-91. ⟨10.1016/j.juro.2009.10.012⟩ |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1016/j.juro.2009.10.012 |
| Popis: | International audience; PURPOSE: The polyamines spermine and spermidine are ubiquitous polycationic structures which are essential for cell proliferation and differentiation. Circulating polyamines, spermine and spermidine, represent valuable prognostic markers in prostate cancer, acute leukemia and supratentorial malignant glioma. We tested whether spermine and spermidine could improve the prognostic ability of several established predictors of cancer specific mortality after partial or radical nephrectomy for renal cell carcinoma. MATERIALS AND METHODS: Testing was performed on 399 patients with stages T(1-4), N(0-2), M(0-1) renal cell carcinoma who were treated with radical or partial nephrectomy at a single institution between 1990 and 2007. Univariable and multivariable Cox regression models tested the prognostic ability of spermine and spermidine levels in cancer specific mortality predictions. Covariates consisted of TNM stage, Fuhrman grade, tumor size and symptom classification. Harrell's concordance index (c-index) quantified accuracy and 200 bootstrap resamples were used to correct for overfit bias. RESULTS: The 5-year cancer specific mortality-free survival of patients with spermine levels 3 or less, 3.1 to 8, 8.1 to 13 and greater than 13 nmol/8x10(9) erythrocytes was 88.8%, 75.8%, 40.2% and 21.8%, respectively. Similarly the 5-year cancer specific mortality-free survival of patients with spermidine levels 12 or less, 12.1 to 15, 15.1 to 21 and greater than 21 nmol/8x10(9) erythrocytes was 79.0%, 56.6%, 53.2% and 27.4%, respectively. On multivariable analyses addressing cancer specific mortality after surgery spermine (p = 0.007) and spermidine (p = 0.04) achieved independent predictor status. Consideration of spermine and spermidine also improved the accuracy of established cancer specific mortality predictors by 2.2% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|